Acer Therapeutics Inc

Acer Therapeutics — Opexa Therapeutics — IPO Roadshow (January 2015)

27 slides from Acer Therapeutics's IPO roadshow presentation, Jan 28, 2015

  1. Slide 1: Opexa Therapeutics, Inc.

    Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-201731 January 28, 2015 Precision Immunotherapy ® Opexa Therapeutics, Inc. NASDAQ: OPXA January 2015 The Woodlands, TX

  2. Slide 2: Free Writing Prospectus Statement

    Free Writing Prospectus Statement • This presentation highlights basic information about us and the offering. Being a summary document, this slide deck does not contain all the information that you should consider before investing. • We have filed a registration statement (including a preliminary pr

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements All statements in this presentation other than those of historical fact, including statements regarding our preclinical and clinical development plans for Tcelna® and OPX-212, our research and other development programs, our ability to undertake certain activities and acco

  4. Slide 4: Opexa Investment Highlights

    Opexa Investment Highlights PIPELINE • Tcelna ®: Phase 2b for secondary progressive multiple sclerosis (SPMS), limited competition, $7BN overall market potential, encouraging prior trials (Phase IIb RRMS, Phase I/II SPMS) • OPX-212: Pre-IND for neuromyelitis optica (NMO), no approved therapies, orph

  5. Slide 5: Offering Summary

    Offering Summary Issuer Opexa Therapeutics, Inc. Exchange/Ticker NASDAQ / OPXA Structure Rights Offering Offering size Up to 28,776,419 Units Each Unit composed of one share of common stock and one warrant Subscription Price TBD Range expected $0.65-$0.75 Exercise price: $0.50 per share from issuanc

  6. Slide 6: Opexa Investment Thesis

    Opexa Investment Thesis Why a Rights Offering? • A successful rights offering would give Opexa sufficient capital to fund operations through 2016. – Complete the ongoing Phase 2b clinical trial in SPMS and release data – Potentially initiate a Phase 1/2 trial with OPX-212 in neuromyelitis optica (NM

  7. Slide 7: How Does Tcelna Work?

    HOW DOES TCELNA WORK? 7

  8. Slide 8: The Root Cause of Multiple Sclerosis

    The Root Cause of Multiple Sclerosis Activated T- cells degrade Myelin and Damage Myelin Producing Cells • MS is an inflammatory disease in which the insulating cover of the nerve fibers (the myelin sheath) in the brain are damaged by the body’s own immune system. There is no Myelin peptide cure for

  9. Slide 9: Tcelna Could Address the Root Cause of Multiple Sclerosis by Preventing Demyelination and Enabling Remyelination

    Tcelna Could Address the Root Cause of Multiple Sclerosis by Preventing Demyelination and Enabling Remyelination • Immune cells, including Tregs, have been primed, or sensitized to specifically target the pathogenic MRTC for elimination or regulation • Elimination of harmful MRTC may lead to: o Stab

  10. Slide 10: Results and Explanation of RRMS & SPMS Clinical Trials

    RESULTS AND EXPLANATION OF RRMS & SPMS CLINICAL TRIALS 10

  11. Slide 11: Business Strategy and Rationale for Pursuing Secondary Progressive MS (SPMS)

    Business Strategy and Rationale for Pursuing Secondary Progressive MS (SPMS) • Opexa completed a Phase 2b clinical study in RRMS patients – Although the primary MRI endpoint was not met, the clinical signal was encouraging – In a subset of more active RRMS subjects, patients treated with Tcelna saw

  12. Slide 12: Phase 2b RRMS prior clinical trial

    Phase 2b RRMS prior clinical trial Tcelna showed 37% improvement over placebo (mITT) (secondary endpoint measurement, primary MRI endpoint measure not met) 37% Reduction in Annualized Relapse Rate (ARR) 0.4 0.35 0.3 0.339 37% Tcelna 0.25 Placebo 0.2 0.214 n=142 0.15 0.1 0.05 0 n=94 n=48 Total mITT p

  13. Slide 13: Phase 2b RRMS Prior Clinical Trial

    Phase 2b RRMS Prior Clinical Trial Reversal of Disability in Prospective Analysis in More Active Patients Sub-population of patients (n=50) with more progressed/active disease profile (baseline ARR >1) Change in Disability (EDSS) Annualized Relapse Rate (ARR) at week 52 at Week 52 2.45 0.7 2.40 2.4

  14. Slide 14: Phase I/II SPMS Prior Clinical Trials

    Phase I/II SPMS Prior Clinical Trials Tcelna Stabilizes Disease in SPMS at 2 Years 80% of patients showed no further disease progression by EDSS at 2 years Stabilization vs. Historical Progression 100% 80% 80% Stable 60% Progressed 40% 40% 20% 20% 0% Tcelna Open Label Historical Disease (n=35) Progr

  15. Slide 15: Tcelna in Secondary Progressive MS

    Tcelna in Secondary Progressive MS 450,000 Individuals in North America diagnosed with MS; 30-45 % potentially have an SPMS diagnosis • Secondary Progressive MS market potential in North America could SPMS exceed $7 billion (for all therapies) Market Size: • Roughly 150,000 SPMS patients in $7 Billi

  16. Slide 16: Tcelna Fast Track Designation by FDA

    Tcelna Lead Program Targeting Secondary Progressive MS patients Fast Track Designation by FDA • Phase 2b trial is fully enrolled: 190 patients with SPMS • Top line data expected in 2H 2016 • Design – Double-blind, 1:1 randomized, placebo-controlled – 35 clinical sites in USA and Canada – Two annual

  17. Slide 17: Merck Serono Agreement

    Merck Serono Agreement Agreement signed 2013; strong potential partner Option and License Agreement for worldwide rights to all Multiple Sclerosis indications, excluding Japan • If Merck Serono exercises option: – Merck Serono to fund any Phase 3, pre-commercial and commercial activities – Merck Ser

  18. Slide 18: OPX-212: Neuromyelitis Optica (NMO)

    OPX-212: NEUROMYELITIS OPTICA (NMO) 18

  19. Slide 19: NMO: A Rare Disease with High Unmet Need and Significant Market Potential

    NMO: A Rare Disease with High Unmet Need and Significant Market Potential • Neuromyelitis optica (NMO) is a rare or orphan autoimmune disease, affecting the optic nerves and the spinal cord • There are no FDA-approved therapies for NMO • Any therapy that could achieve tolerization of the AQP-4 react

  20. Slide 20: Recent and Upcoming Expected Milestones

    Recent and Upcoming Expected Milestones 2H 2015: Initiate Phase I/II 1H 2017: Top line results clinical study with OPX-212 in expected from Phase I/II trial NMO (subject to IND with OPX-212 in NMO (subject 2H 2014: Initiate 2H 2016: Results from acceptance and financing) to IND acceptance and financ

  21. Slide 21: Experienced Management Team and Board of Directors

    Experienced Management Team and Board of Directors Neil Warma, President & CEO, Director › 19+ years international healthcare experience with large Pharma and emerging Board of Directors biotechnology companies › Former Senior Management, Novartis Pharmaceuticals, Basel, Switzerland Timothy Barabe B

  22. Slide 22: SPMS Scientific Advisory Board

    SPMS Scientific Advisory Board Dawn McGuire, M.D., FAAN (Chair) • Advisory Council of the Gill Heart Institute • Former Vice President of Clinical Research at Elan Pharmaceuticals Hans-Peter Hartung, M.D • Chair of Neurology at Heinrich-Heine University, Düsseldorf • Executive Board member of ECTRIM

  23. Slide 23: Appendix

    APPENDIX 23

  24. Slide 24: ImmPath: Proprietary Drug Development Platform

    IMMPATH ®: PROPRIETARY DRUG DEVELOPMENT PLATFORM 24

  25. Slide 25: Personalized T-cell vaccines

    Personalized T-cell vaccines Consisting of Attenuated Antigen Specific T-cell Clones Personalized T-cell Vaccine • Opexa identifies the exact T-cell responsible for T-cell-mediated autoimmune damage, expands the T-cells in cGMP facility Tcelna ® • Therapeutic dose of attenuated T-cell clones is inje

  26. Slide 26: Business Differentiator: Manufacturing Process

    Business Differentiator: Manufacturing Process Designed for commercialization, Owned and managed by Opexa 14 days 35 days 1 day Epitope Profiling Manufacturing and QC Dispensation - Red Cross - Blood Group Alliance Cryopreservation Epitope Profiling Expansion of antigen specific T-cells Formulation/

  27. Slide 27: Comprehensive Process to Determine Optimal Additional Indications Beyond Secondary-Progressive MS

    Comprehensive Process to Determine Optimal Additional Indications Beyond Secondary-Progressive MS Potential Disease Targets off Platform Addison’s disease Evaluation Criteria Autoimmune hemolytic anemia Celiac Disease • Unmet medical need Goodpasture’s syndrome • Competitive landscape Short List of

Opexa Therapeutics — IPO Roadshow (January 2015) on 6ix